A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.
Phase 3, Open-Label, Multi-Center, Double-Blind, Randomized, Parallel Group Study Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin, Administered Once Daily (QD) Compared to Fixed Combination Ezetimibe/Simvastatin for 6 Weeks in Subjects With Dyslipidemia.
1 other identifier
interventional
1,784
1 country
123
Brief Summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. Cholesterol levels will be measured over six weeks in subjects being treated with two different kinds of combination cholesterol medications to see how the different treatments compare to one another.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Jan 2006
Shorter than P25 for phase_3
123 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 19, 2005
CompletedFirst Posted
Study publicly available on registry
December 20, 2005
CompletedStudy Start
First participant enrolled
January 1, 2006
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2007
CompletedDecember 10, 2007
December 1, 2006
December 19, 2005
December 6, 2007
Conditions
Outcome Measures
Primary Outcomes (1)
Percent change in LDL-C and HDL-C from baseline, after six weeks of treatment.
Secondary Outcomes (1)
Changes in other lipid parameters and other biomarkers.
Interventions
Eligibility Criteria
You may qualify if:
- Specific LDL-C levels based on CHD risk after a six-week washout period.
You may not qualify if:
- Women who are pregnant or lactating, or planning to become pregnant.
- Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors.
- Subjects requiring systemic steroids
- Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Pfizerlead
Study Sites (123)
Pfizer Investigational Site
Birmingham, Alabama, 35209-7802, United States
Pfizer Investigational Site
Birmingham, Alabama, 35235, United States
Pfizer Investigational Site
Chandler, Arizona, 85224, United States
Pfizer Investigational Site
Mesa, Arizona, 85201, United States
Pfizer Investigational Site
Jonesboro, Arkansas, 72401, United States
Pfizer Investigational Site
Anaheim, California, 92804, United States
Pfizer Investigational Site
Escondido, California, 92025-4284, United States
Pfizer Investigational Site
Fresno, California, 93720, United States
Pfizer Investigational Site
Los Altos, California, 94024, United States
Pfizer Investigational Site
Los Angeles, California, 90015, United States
Pfizer Investigational Site
Palm Springs, California, 92262, United States
Pfizer Investigational Site
Paramount, California, 90723, United States
Pfizer Investigational Site
San Diego, California, 92128, United States
Pfizer Investigational Site
Santa Rose, California, 95405, United States
Pfizer Investigational Site
Walnut Creek, California, 94598, United States
Pfizer Investigational Site
Westlake Village, California, 91361, United States
Pfizer Investigational Site
Golden, Colorado, 80401, United States
Pfizer Investigational Site
New Haven, Connecticut, 06519-1600, United States
Pfizer Investigational Site
Newark, Delaware, 19713, United States
Pfizer Investigational Site
Washington D.C., District of Columbia, 20010, United States
Pfizer Investigational Site
Atlantis, Florida, 33462, United States
Pfizer Investigational Site
Boca Raton, Florida, 33486, United States
Pfizer Investigational Site
Daytona Beach, Florida, 32114, United States
Pfizer Investigational Site
DeFuniak Springs, Florida, 32435, United States
Pfizer Investigational Site
Destin, Florida, 32541, United States
Pfizer Investigational Site
Lakeland, Florida, 33805, United States
Pfizer Investigational Site
Miami, Florida, 33136, United States
Pfizer Investigational Site
Miami, Florida, 33144, United States
Pfizer Investigational Site
Miami, Florida, 33173, United States
Pfizer Investigational Site
Orlando, Florida, 32806, United States
Pfizer Investigational Site
Pensacola, Florida, 32504-8721, United States
Pfizer Investigational Site
Atlanta, Georgia, 30309, United States
Pfizer Investigational Site
Atlanta, Georgia, 30328, United States
Pfizer Investigational Site
Atlanta, Georgia, 30342, United States
Pfizer Investigational Site
Honolulu, Hawaii, 96814, United States
Pfizer Investigational Site
Aurora, Illinois, 60504, United States
Pfizer Investigational Site
Chicago, Illinois, 60637, United States
Pfizer Investigational Site
Rockford, Illinois, 61108, United States
Pfizer Investigational Site
Springfield, Illinois, 62701, United States
Pfizer Investigational Site
Evansville, Indiana, 47712, United States
Pfizer Investigational Site
Evansville, Indiana, 47713, United States
Pfizer Investigational Site
Evansville, Indiana, 47714, United States
Pfizer Investigational Site
Des Moines, Iowa, 50314, United States
Pfizer Investigational Site
Newton, Kansas, 67114, United States
Pfizer Investigational Site
Overland Park, Kansas, 66210, United States
Pfizer Investigational Site
Pratt, Kansas, 67124, United States
Pfizer Investigational Site
Topeka, Kansas, 66606, United States
Pfizer Investigational Site
Edgewood, Kentucky, 41017, United States
Pfizer Investigational Site
Erlanger, Kentucky, 41018, United States
Pfizer Investigational Site
Louisville, Kentucky, 40205-3374, United States
Pfizer Investigational Site
Columbia, Maryland, 21044-2914, United States
Pfizer Investigational Site
Ayer, Massachusetts, 01432, United States
Pfizer Investigational Site
Boston, Massachusetts, 02111, United States
Pfizer Investigational Site
Boston, Massachusetts, 02114, United States
Pfizer Investigational Site
Milford, Massachusetts, 01757, United States
Pfizer Investigational Site
Bloomfield Hills, Michigan, 48302, United States
Pfizer Investigational Site
Grand Rapids, Michigan, 49525, United States
Pfizer Investigational Site
Troy, Michigan, 48098, United States
Pfizer Investigational Site
Brooklyn Center, Minnesota, 55430, United States
Pfizer Investigational Site
Edina, Minnesota, 55435, United States
Pfizer Investigational Site
Saint Cloud, Minnesota, 56303-1901, United States
Pfizer Investigational Site
Columbia, Missouri, 65212, United States
Pfizer Investigational Site
Jefferson City, Missouri, 65109, United States
Pfizer Investigational Site
Manchester, Missouri, 63021, United States
Pfizer Investigational Site
Springfield, Missouri, 65804, United States
Pfizer Investigational Site
Springfield, Missouri, 65807, United States
Pfizer Investigational Site
Omaha, Nebraska, 68106, United States
Pfizer Investigational Site
Omaha, Nebraska, 68114, United States
Pfizer Investigational Site
Omaha, Nebraska, 68130, United States
Pfizer Investigational Site
Las Vegas, Nevada, 89106, United States
Pfizer Investigational Site
Las Vegas, Nevada, 89128, United States
Pfizer Investigational Site
Cooperstown, New York, 13326, United States
Pfizer Investigational Site
Endwell, New York, 13760, United States
Pfizer Investigational Site
Lewiston, New York, 14092, United States
Pfizer Investigational Site
Manlius, New York, 13104, United States
Pfizer Investigational Site
Rochester, New York, 14609, United States
Pfizer Investigational Site
Rochester, New York, 14618, United States
Pfizer Investigational Site
Syracuse, New York, 13202, United States
Pfizer Investigational Site
West Seneca, New York, 14224, United States
Pfizer Investigational Site
Cary, North Carolina, 27511, United States
Pfizer Investigational Site
Charlotte, North Carolina, 28209-3734, United States
Pfizer Investigational Site
Huntersville, North Carolina, 28078, United States
Pfizer Investigational Site
Monroe, North Carolina, 28112, United States
Pfizer Investigational Site
Raleigh, North Carolina, 27609, United States
Pfizer Investigational Site
Wilmington, North Carolina, 28412, United States
Pfizer Investigational Site
Winston-Salem, North Carolina, 27103-3315, United States
Pfizer Investigational Site
Winston-Salem, North Carolina, 27103, United States
Pfizer Investigational Site
Cincinnati, Ohio, 45219, United States
Pfizer Investigational Site
Cleveland, Ohio, 44195, United States
Pfizer Investigational Site
Fairview Park, Ohio, 44126, United States
Pfizer Investigational Site
Beaver, Pennsylvania, 15009, United States
Pfizer Investigational Site
Bensalem, Pennsylvania, 19020, United States
Pfizer Investigational Site
Doylestown, Pennsylvania, 18901, United States
Pfizer Investigational Site
Harleysville, Pennsylvania, 19438, United States
Pfizer Investigational Site
Lancaster, Pennsylvania, 17603, United States
Pfizer Investigational Site
Pittsburgh, Pennsylvania, 15213, United States
Pfizer Investigational Site
Pittsburgh, Pennsylvania, 15224, United States
Pfizer Investigational Site
Sayre, Pennsylvania, 18840, United States
Pfizer Investigational Site
Lincoln, Rhode Island, 02865, United States
Pfizer Investigational Site
Providence, Rhode Island, 02906, United States
Pfizer Investigational Site
Anderson, South Carolina, 29621, United States
Pfizer Investigational Site
Mt. Pleasant, South Carolina, 29464, United States
Pfizer Investigational Site
Simpsonville, South Carolina, 29681, United States
Pfizer Investigational Site
Bristol, Tennessee, 37620, United States
Pfizer Investigational Site
Chattanooga, Tennessee, 37404, United States
Pfizer Investigational Site
Germantown, Tennessee, 38138, United States
Pfizer Investigational Site
Johnson City, Tennessee, 37601, United States
Pfizer Investigational Site
Memphis, Tennessee, 38104, United States
Pfizer Investigational Site
Memphis, Tennessee, 38119, United States
Pfizer Investigational Site
Memphis, Tennessee, 38120, United States
Pfizer Investigational Site
Memphis, Tennessee, 38128, United States
Pfizer Investigational Site
Selmer, Tennessee, 38375, United States
Pfizer Investigational Site
Arlington, Texas, 76017, United States
Pfizer Investigational Site
Houston, Texas, 77030, United States
Pfizer Investigational Site
Houston, Texas, 77054, United States
Pfizer Investigational Site
San Antonio, Texas, 78229, United States
Pfizer Investigational Site
San Antonio, Texas, 78238, United States
Pfizer Investigational Site
Bountiful, Utah, 84010, United States
Pfizer Investigational Site
Salt Lake City, Utah, 84102, United States
Pfizer Investigational Site
Newport News, Virginia, 23606, United States
Pfizer Investigational Site
Norfolk, Virginia, 23502, United States
Pfizer Investigational Site
Renton, Washington, 98055, United States
Pfizer Investigational Site
Spokane, Washington, 99216, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Pfizer CT.gov Call Center
Pfizer
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
December 19, 2005
First Posted
December 20, 2005
Study Start
January 1, 2006
Study Completion
January 1, 2007
Last Updated
December 10, 2007
Record last verified: 2006-12